Placement & SPP to raise $10 million - Funded to FY26
Filed with ASX · · 6 pages · English
Recce Pharmaceuticals Ltd. on 6ix
Earlier from Recce Pharmaceuticals
- Phase I/II UTI/Urosepsis Rapid Infusion Trial Complete
- Ethics Approval Broadens to All Topical Infections
- Further R&D Rebate Approved
- R327 added to WHO List of Antibacterial Products
- Cohort Dosing Complete Ph I/II UTI/Urosepsis Clinical Trial
Later from Recce Pharmaceuticals
- R327 Efficacy against WHO Priority Pathogen Acinetobacter B
- US Department of Defense Grants US $2m for R327G
- Recce Pharmaceuticals Receives $2 Million Grant from U.S. Department of Defense for RECCE® 327 Gel
- Successful Completion of Share Purchase Plan
- Recce Pharmaceuticals Announces Successful Completion of Share Purchase Plan
Follow Recce Pharmaceuticals into a list and get an email when it puts out news.
Follow Recce Pharmaceuticals